Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISE: Pegunigalsidase Alfa in Japanese Patients With Fabry Disease
NCT05710692Phase 3Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Aug 2023
- Primary completion
- Oct 2027
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pegunigalsidase alfa in Fabry disease (FD), sponsored by Chiesi Farmaceutici S.p.A.. Started Aug 2023; status: recruiting.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT05710692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05710692.